Skip to main content

Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.

Publication ,  Journal Article
Raskino, C; Pearson, DA; Baker, CJ; Lifschitz, MH; O'Donnell, K; Mintz, M; Nozyce, M; Brouwers, P; McKinney, RE; Jimenez, E; Englund, JA
Published in: Pediatrics
September 1999

OBJECTIVES: To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children. METHODS: Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to <30 months of age or 30 months to 18 years of age) and randomized in equal proportions to the three treatment groups. RESULTS: Combination ZDV and ddI therapy was superior to either ZDV or ddI monotherapy for most of the CNS outcomes evaluated. Treatment differences were observed within both age strata. ZDV monotherapy showed a modest statistically significant improvement in cognitive performance compared with ddI monotherapy during the initial 24 weeks, but for subsequent protection against CNS deterioration no clear difference was observed between the two monotherapy arms. CONCLUSIONS: Combination therapy with ZDV and ddI was more effective than either of the two monotherapies against CNS manifestations of human immunodeficiency virus disease. The results of this study did not indicate a long-term beneficial effect for ZDV monotherapy compared with ddI monotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 1999

Volume

104

Issue

3

Start / End Page

e32

Location

United States

Related Subject Headings

  • Zidovudine
  • Reverse Transcriptase Inhibitors
  • Pediatrics
  • Motor Skills
  • Male
  • Intelligence Tests
  • Infant
  • Humans
  • HIV Infections
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raskino, C., Pearson, D. A., Baker, C. J., Lifschitz, M. H., O’Donnell, K., Mintz, M., … Englund, J. A. (1999). Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics, 104(3), e32. https://doi.org/10.1542/peds.104.3.e32
Raskino, C., D. A. Pearson, C. J. Baker, M. H. Lifschitz, K. O’Donnell, M. Mintz, M. Nozyce, et al. “Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.Pediatrics 104, no. 3 (September 1999): e32. https://doi.org/10.1542/peds.104.3.e32.
Raskino C, Pearson DA, Baker CJ, Lifschitz MH, O’Donnell K, Mintz M, Nozyce M, Brouwers P, McKinney RE, Jimenez E, Englund JA. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics. 1999 Sep;104(3):e32.

Published In

Pediatrics

DOI

EISSN

1098-4275

Publication Date

September 1999

Volume

104

Issue

3

Start / End Page

e32

Location

United States

Related Subject Headings

  • Zidovudine
  • Reverse Transcriptase Inhibitors
  • Pediatrics
  • Motor Skills
  • Male
  • Intelligence Tests
  • Infant
  • Humans
  • HIV Infections
  • Female